Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.


Journal

Journal of the National Comprehensive Cancer Network : JNCCN
ISSN: 1540-1413
Titre abrégé: J Natl Compr Canc Netw
Pays: United States
ID NLM: 101162515

Informations de publication

Date de publication:
01 2022
Historique:
entrez: 6 1 2022
pubmed: 7 1 2022
medline: 22 3 2022
Statut: ppublish

Résumé

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide management of advanced RCC, the NCCN Kidney Cancer Panel has categorized all systemic kidney cancer therapy regimens as "Preferred," "Other Recommended Regimens," or "Useful in Certain Circumstances." This categorization provides guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include pre-existing comorbidities, nature of the disease, and in some cases consideration of access to agents. This article summarizes surgical and systemic therapy recommendations for patients with relapsed or stage IV RCC.

Identifiants

pubmed: 34991070
doi: 10.6004/jnccn.2022.0001
pmc: PMC10191161
mid: NIHMS1895044
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

71-90

Subventions

Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States

Références

Int J Oncol. 2001 Aug;19(2):379-82
pubmed: 11445855
Cancer. 2010 Sep 15;116(18):4256-65
pubmed: 20549832
Clin Cancer Res. 2005 Aug 1;11(15):5472-80
pubmed: 16061863
J Urol. 2005 Jun;173(6):1889-92
pubmed: 15879769
Clin Genitourin Cancer. 2018 Oct;16(5):e997-e1002
pubmed: 29903415
Eur Urol. 2017 Aug;72(2):171-174
pubmed: 28359734
Cancer. 2010 Jul 15;116(14):3378-88
pubmed: 20564061
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
J Urol. 2001 Jul;166(1):54-8
pubmed: 11435822
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Cancer. 2005 Aug 1;104(3):511-20
pubmed: 15973740
Lancet Oncol. 2013 May;14(6):552-62
pubmed: 23598172
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Oncology. 2011;80(3-4):214-8
pubmed: 21720184
J Clin Oncol. 2014 Mar 10;32(8):760-7
pubmed: 24297950
J Urol. 2007 Aug;178(2):425-8; discussion 428
pubmed: 17561167
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Br J Cancer. 2018 May;118(9):1176-1178
pubmed: 29576624
Eur Urol. 2008 Dec;54(6):1373-8
pubmed: 18692304
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
J Exp Med. 1985 May 1;161(5):1169-88
pubmed: 3886826
Eur Urol. 2016 May;69(5):866-74
pubmed: 26626617
Ann Oncol. 2005 Oct;16(10):1688-94
pubmed: 16006586
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
Mod Pathol. 2007 Sep;20(9):914-20
pubmed: 17643096
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Lancet Oncol. 2016 Jan;17(1):e4-5
pubmed: 26758760
BJU Int. 2016 Feb;117(2):260-5
pubmed: 25307281
Cancer Res Treat. 2018 Apr;50(2):488-494
pubmed: 28546525
Eur Urol. 2021 Aug;80(2):162-170
pubmed: 33867192
Ann Oncol. 2012 Apr;23(4):973-80
pubmed: 21890909
Lancet Oncol. 2013 Dec;14(13):1287-94
pubmed: 24206640
N Engl J Med. 2018 Aug 02;379(5):417-427
pubmed: 29860937
Oncology. 2009;76(5):350-4
pubmed: 19321976
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
Strahlenther Onkol. 2010 Apr;186(4):210-7
pubmed: 20165820
Cancer. 2010 Dec 1;116(23):5383-90
pubmed: 20806321
Cancer. 2009 Jan 1;115(1):61-7
pubmed: 19051290
J Immunother Cancer. 2018 Jan 29;6(1):9
pubmed: 29378660
Cancer Immunol Res. 2018 Jul;6(7):758-765
pubmed: 29748390
J Urol. 2007 Jul;178(1):35-40; discussion 40
pubmed: 17521678
Drugs Aging. 2013 Nov;30(11):877-86
pubmed: 24072355
BMC Urol. 2013 May 21;13:26
pubmed: 23688003
Lancet Oncol. 2016 Sep;17(9):1317-24
pubmed: 27498080
Eur J Cancer. 2013 Apr;49(6):1287-96
pubmed: 23321547
Lancet Oncol. 2016 Mar;17(3):378-388
pubmed: 26794930
Pract Radiat Oncol. 2012 Oct-Dec;2(4):e95-e100
pubmed: 24674192
Eur J Cancer. 2017 Sep;83:237-246
pubmed: 28756136
Eur Urol. 2021 Oct;80(4):417-424
pubmed: 34187771
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
N Engl J Med. 2014 May 1;370(18):1769-70
pubmed: 24785224
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Urology. 2007 Nov;70(5):878-82
pubmed: 18068443
J Clin Oncol. 2016 Nov 10;34(32):3846-3853
pubmed: 27601542
Cancer. 2005 Jun 15;103(12):2517-25
pubmed: 15880379
Eur Urol. 2017 Dec;72(6):962-971
pubmed: 28262413
J Urol. 2009 Jul;182(1):29-34; discussion 34
pubmed: 19447417
Radiology. 2003 Jan;226(1):33-46
pubmed: 12511666
Cancer. 2002 May 15;94(10):2590-5
pubmed: 12173325
Ann Oncol. 2020 Aug;31(8):1030-1039
pubmed: 32339648
Lancet Oncol. 2020 Jan;21(1):95-104
pubmed: 31810797
Future Oncol. 2016 Mar;12(5):637-45
pubmed: 26837701
J Clin Oncol. 2021 Mar 20;39(9):1029-1039
pubmed: 33529058
Am J Surg Pathol. 2012 Sep;36(9):1265-78
pubmed: 22895263
J Clin Oncol. 2011 Mar 20;29(9):1125-32
pubmed: 21343556
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Cancer. 2000 Aug 1;89(3):604-14
pubmed: 10931460
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Clin Oncol. 2009 Dec 1;27(34):5788-93
pubmed: 19884559
J Clin Oncol. 2020 Nov 1;38(31):3672-3684
pubmed: 32915679
Clin Genitourin Cancer. 2017 Aug;15(4):e609-e614
pubmed: 28108284
Lancet Oncol. 2021 Jul;22(7):946-958
pubmed: 34143969
J Urol. 2011 Jan;185(1):60-6
pubmed: 21074201
Lancet. 2021 Feb 20;397(10275):695-703
pubmed: 33592176
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
J Urol. 2006 Jul;176(1):40-3; discussion 43
pubmed: 16753362
N Engl J Med. 2003 Jul 31;349(5):427-34
pubmed: 12890841
Clin Genitourin Cancer. 2013 Sep;11(3):270-5
pubmed: 23665131
J Clin Oncol. 2005 Feb 1;23(4):832-41
pubmed: 15681528
BJU Int. 2007 Sep;100(3):552-5
pubmed: 17555475
Eur Urol. 2007 Jul;52(1):155-62
pubmed: 17316970
Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1
pubmed: 28410911
Ann Oncol. 2013 Apr;24(4):1026-31
pubmed: 23180114
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Mod Pathol. 2009 Jun;22 Suppl 2:S2-S23
pubmed: 19494850
J Urol. 2007 May;177(5):1698-702
pubmed: 17437788
Semin Oncol. 2016 Oct;43(5):566-574
pubmed: 27899189
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1744-8
pubmed: 21596489
JAMA. 2006 Jun 7;295(21):2516-24
pubmed: 16757724
Eur J Cancer. 2008 Nov;44(16):2485-95
pubmed: 18783939
Cancer. 2018 Mar 1;124(5):934-942
pubmed: 29266183
Eur J Cancer. 2018 Jul;98:38-47
pubmed: 29864737
Lancet. 2008 Aug 9;372(9637):449-56
pubmed: 18653228
Br J Cancer. 2005 May 23;92(10):1855-61
pubmed: 15870716
Med Oncol. 2009;26(2):202-9
pubmed: 19229667
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
Cancer. 2004 Jun 15;100(12):2613-21
pubmed: 15197804
J Clin Oncol. 2006 Jan 1;24(1):16-24
pubmed: 16330672
BJU Int. 2017 Dec;120(6):782-792
pubmed: 27860149
Eur J Cancer. 2016 Dec;69:226-235
pubmed: 27680407
N Engl J Med. 2007 May 31;356(22):2271-81
pubmed: 17538086
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
J Clin Oncol. 2007 Mar 1;25(7):884-96
pubmed: 17327610
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
J Clin Oncol. 2003 Aug 15;21(16):3127-32
pubmed: 12915604
PLoS One. 2017 Sep 8;12(9):e0184423
pubmed: 28886175
Lancet. 2011 Dec 3;378(9807):1931-9
pubmed: 22056247
N Engl J Med. 2018 Aug 2;379(5):481-482
pubmed: 29860908
J Clin Oncol. 2017 Dec 1;35(34):3851-3858
pubmed: 28678668
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
J Clin Oncol. 2002 Jan 1;20(1):289-96
pubmed: 11773181
Clin Genitourin Cancer. 2019 Feb;17(1):1-6
pubmed: 30287223
J Clin Oncol. 2005 Feb 10;23(5):965-72
pubmed: 15613696
Cancer. 2005 Sep 1;104(5):968-74
pubmed: 16007683
Cancer. 2003 Sep 1;98(5):962-9
pubmed: 12942563
J Urol. 2010 Apr;183(4):1309-15
pubmed: 20171681
J Clin Oncol. 2005 Jan 1;23(1):133-41
pubmed: 15625368
Fam Cancer. 2014 Dec;13(4):637-44
pubmed: 25012257
Cancer Res. 2004 Oct 1;64(19):7099-109
pubmed: 15466206
Eur Urol. 2007 Oct;52(4):1140-5
pubmed: 17336449
J Clin Oncol. 2009 Jul 10;27(20):3312-8
pubmed: 19451442
J Clin Oncol. 2009 Aug 1;27(22):3584-90
pubmed: 19487381
J Clin Oncol. 2006 Jan 1;24(1):25-35
pubmed: 16314617

Auteurs

Robert J Motzer (RJ)

Memorial Sloan Kettering Cancer Center.

Eric Jonasch (E)

The University of Texas MD Anderson Cancer Center.

Neeraj Agarwal (N)

Huntsman Cancer Institute at the University of Utah.

Ajjai Alva (A)

University of Michigan Rogel Cancer Center.

Michael Baine (M)

Fred & Pamela Buffet Cancer Center.

Kathryn Beckermann (K)

Vanderbilt-Ingram Cancer Center.

Maria I Carlo (MI)

Memorial Sloan Kettering Cancer Center.

Toni K Choueiri (TK)

Dana-Farber/Brigham and Women's Cancer Center.

Brian A Costello (BA)

Mayo Clinic Cancer Center.

Ithaar H Derweesh (IH)

UC San Diego Moores Cancer Center.

Arpita Desai (A)

UCSF Helen Diller Family Comprehensive Cancer Center.

Yasser Ged (Y)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Saby George (S)

Roswell Park Comprehensive Cancer Center.

John L Gore (JL)

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

Naomi Haas (N)

Abramson Cancer Center at the University of Pennsylvania.

Steven L Hancock (SL)

Stanford Cancer Institute.

Payal Kapur (P)

UT Southwestern Simmons Comprehensive Cancer Center.

Christos Kyriakopoulos (C)

University of Wisconsin Carbone Cancer Center.

Elaine T Lam (ET)

University of Colorado Cancer Center.

Primo N Lara (PN)

UC Davis Comprehensive Cancer Center.

Clayton Lau (C)

City of Hope National Medical Center.

Bryan Lewis (B)

Kidney Cancer Coalition.

David C Madoff (DC)

Yale Cancer Center/Smilow Cancer Hospital.

Brandon Manley (B)

Moffitt Cancer Center.

M Dror Michaelson (MD)

Massachusetts General Hospital Cancer Center.

Amir Mortazavi (A)

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

Lakshminarayanan Nandagopal (L)

O'Neal Comprehensive Cancer Center at UAB.

Elizabeth R Plimack (ER)

Fox Chase Cancer Center.

Lee Ponsky (L)

Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

Sundhar Ramalingam (S)

Duke Cancer Institute.

Brian Shuch (B)

UCLA Jonsson Comprehensive Cancer Center.

Zachary L Smith (ZL)

Siteman Cancer Center at Barnes- Jewish Hospital and Washington University School of Medicine.

Jeffrey Sosman (J)

Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Mary A Dwyer (MA)

National Comprehensive Cancer Network.

Lisa A Gurski (LA)

National Comprehensive Cancer Network.

Angela Motter (A)

National Comprehensive Cancer Network.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH